tolterodine tartrate tablets
DETROL LA Capsules contain tolterodine tartrate. The active moiety, tolterodine, is a muscarinic receptor antagonist.
DETROL LA Capsules are once daily extended release capsules indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Published Studies Related to Detrol (Tolterodine)
Effects of terazosin and tolterodine on ureteral stent related symptoms: a
double-blind placebo-controlled randomized clinical trial. 
discomfort... CONCLUSIONS: Terazosin plus tolterodine improves ureteral stent-related
Efficacy of tolterodine for medical treatment of intramural ureteral stone with vesical irritability. [2011.06]
We evaluated the clinical results of tolterodine in treating impacted stones in the intramural ureter with symptoms of vesical irritability. A total of 80 patients with intramural ureter stones were included in the study from December 2007 to November 2009... While our study demonstrated no improvement in expulsion rate, Tolterodine reduced the common symptoms of frequency, urgency, intensity of the pain episodes and discomfort often associated with intramural ureter stone.
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. [2011.05]
OBJECTIVE: * To show the superior efficacy of fesoterodine over tolterodine extended release (ER) in a placebo-controlled overactive bladder (OAB) trial with predefined treatment comparisons for both diary measures and patient-reported outcomes... CONCLUSIONS: * In this randomized study, which is the largest to compare antimuscarinic efficacy performed to date, fesoterodine 8 mg was superior to tolterodine ER 4 mg for UUI episodes, micturitions and urgency episodes, as well as for self-reported patient assessments of bladder-related problems, urgency, symptom bother and health-related quality of life. * The superiority of fesoterodine 8 mg over tolterodine ER 4 mg was observed as early as 3 weeks after escalation from fesoterodine 4 mg for most outcomes. These data may have important implications for the clinical management of OAB patients previously treated with tolterodine ER. (c) 2010 THE AUTHORS. BJU INTERNATIONAL (c) 2010 BJU INTERNATIONAL.
[Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity]. [2011.04]
OBJECTIVE: To evaluate the efficacy and safety of Tolterodine Tartrate combined with the alpha-receptor blocker in the treatment of benign prostatic hyperplasia with detrusor overactivity (BPH-DO)... CONCLUSION: The combined use of Tolterodine Tartrate and the alpha-receptor blocker can effectively relieve the symptoms of dysuria, urinary frequency and urinary urgency in patients with BPH-DO, with neither significant adverse effects on the maximum flow rate and residual urine volume nor increase in the incidence of acute urinary retention.
The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia. [2011.04]
AIM: To determine the efficacy of toterodine extended release (ER) treatment for 1 year in older men with benign prostatic hyperplasia (BPH) and storage symptoms treated with alpha-blockers and/or 5-alpha-reductase inhibitors (5ARI)... CONCLUSIONS: This longer comparative study indicated that additive treatment with tolterodine ER in older men with BPH/BOO and significant storage symptoms is a beneficial and safe therapeutic option. Copyright (c) 2011 Wiley-Liss, Inc.
Clinical Trials Related to Detrol (Tolterodine)
Efficacy and Safety Study of Dutasteride Combined With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS) [Recruiting]
This is an investigator-initiated study of safety, efficacy and tolerability of dutasteride
given for 18 months, including a 1-year double-blind randomized co-administration with
either tolterodine ER or placebo in men suffering from lower urinary tract symptoms (LUTS)
including urgency and frequency, with or without urgency urinary incontinence (i. e.,
overactive bladder (OAB) symptoms).
Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet [Completed]
To evaluate efficacy of tolterodine extended release formulation compared with immediate
release formulation in subjects with symptoms of overactive bladder
A Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder (OAB) (MK-4618-008 AM1 EXT) [Recruiting]
This is a 2-part study to assess if MK-4618 reduces the number daily urinations more
effectively than placebo in participants with overactive bladder (OAB).
A Study of the Pharmacokinetics and Pharmacodynamics of MK4618 in Women With Overactive Bladder (MK-4618-004 AM1) [Recruiting]
The study is designed to investigate the effects of an investigational drug, MK-4618 on
maximum urinary bladder capacity in women with overactive bladder. Overactive bladder is
best described as urgency and frequency of urination, with or without involuntary urination
and/or the need to awaken during the night to urinate.
A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause. [Recruiting]
This study is being done to compare frequency of urination during the night when women take
tolterodine tablets vs. when they take placebo tablets.
We will also measure whether between these two treatment conditions there are any
differences in women's sleep, mood and performance on cognitive tests.
Reports of Suspected Detrol (Tolterodine) Side Effects
Drug Ineffective (29),
DRY Mouth (11),
Urinary Incontinence (8),
Abdominal Pain Upper (6),
Bladder Disorder (6),
Mental Status Changes (5), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Detrol has an overall score of 2. The effectiveness score is 4 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Detrol review by 51 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Marginally Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || urgency to urinate|
|Dosage & duration:|| || 4mg taken 1x day for the period of 3 mo|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || some reduced frequency in urination. didn't seem to reduce urgency
a;lkjd ajalkd; adlfjsldj safljslfk fdsakjs sfdlkjsl salfjsdl sdfljlksd lksdafkj;s saldfjslk sdfkslfkj sdflkjslk|
|Side effects:|| || dry mouth, thirst.
alsdfjl asldfjslk sfldkjlkjs sldfkjsl sljkljksdf ljsadflk sdf slkdjafl sdljlk sldfjklsak sdalkj slkjsdlkj ljsljflk sllkjsdflkj|
|Comments:|| || take once per day. was told it could take up to 6 weeks to see any results. took once per day as prescribed in the mornings with water but without food. |
Page last updated: 2014-11-30